A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2004
11/11/2004	WO2004087690A3 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
11/11/2004	WO2004085403B1 Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
11/11/2004	WO2004075720A3 Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson’s disease in humans
11/11/2004	WO2004071517A3 Uses of il-23 related reagents
11/11/2004	WO2004063152A3 Lansoprazole formulations and related processes and methods
11/11/2004	WO2004056306A3 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
11/11/2004	WO2004038407A3 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
11/11/2004	WO2003101380A3 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
11/11/2004	WO2003059264A9 Methods for the induction of professional and cytokine-producing regulatory cells
11/11/2004	WO2003038052A3 Nucleic acid-associated proteins
11/11/2004	WO2002096350A3 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
11/11/2004	US20040225130 Imidazolyl derivatives as corticotropin releasing factor inhibitors
11/11/2004	US20040225123 Substituted phenyl naphthalenes as estrogenic agents
11/11/2004	US20040225118 31 human secreted proteins
11/11/2004	US20040225020 optically pure (-)-bupropion is effective in aiding or achieving smoking cessation while avoiding adverse effects associated with the administration of racemic bupropion.
11/11/2004	US20040225013 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
11/11/2004	US20040225008 such as N-(4-{[methyl-(2-propynyl)amino]methyl}phenyl)-2-thiophenecarboximidamine; for inhibiting nitrogen oxide synthases and/or monoamine oxidases
11/11/2004	US20040225006 Useful in treatment and prophylaxis of conditions mediated by s-CD23 or tumor necrosis factor; autoimmune disease, inflammation, allergy
11/11/2004	US20040225003 4,6-Dimethyl-3-{[3'-(N,N-dimethylaminomethyl)-4-hydroxy-4'-(3''-methoxyphenyl)-cyclohexylamino]-methyl}-1H-indole 2-carboxylic acid ethyl ester or other derivatives of substituted indoles; for treatment or prevention of neurodegenerative diseases, psychological disorders, AIDS, inflammation or allergies
11/11/2004	US20040225001 Imidazolyl derivatives as corticotropin releasing factor inhibitors
11/11/2004	US20040224996 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/11/2004	US20040224993 Diphenylurea compounds
11/11/2004	US20040224980 Compounds used as drugs in solvents as analgesics
11/11/2004	US20040224977 Racemic mixtures for treatment of diseases with alpha 7nicotinic acetyl chloline administering
11/11/2004	US20040224976 Azabicyclic compounds for the treatment of disease
11/11/2004	US20040224970 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
11/11/2004	US20040224969 Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds
11/11/2004	US20040224966 Enzyme inhibitors as drugs for cardiovascular disorders, aids, alzheimers disease or urogenital disorders
11/11/2004	US20040224965 Treatment of cardiovascular disorders, thrombosis, surgery and nhe inhibitors
11/11/2004	US20040224964 Corticotropin Releasing factor antagonist as drugs
11/11/2004	US20040224958 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
11/11/2004	US20040224954 Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
11/11/2004	US20040224953 Fused bicyclic-substituted amines as histamine-3 receptor ligands
11/11/2004	US20040224952 e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight.
11/11/2004	US20040224942 Use of N-desmethylclozapine to treat human neuropsychiatric disease
11/11/2004	US20040224938 Substituted benzo [b] azepin-2-one compounds
11/11/2004	US20040224929 Novel vitamin D analogs
11/11/2004	US20040224925 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
11/11/2004	US20040224924 Programming a specific course and rate for a parent drug compound's metabolism that leads to an inactive or weakly active and non-toxic metabolite when the parent drug compound is administered, comprising modifying the parent drug compound by forming one or more of a predetermined chemical arrangement
11/11/2004	US20040224911 Transporters and ion channels
11/11/2004	US20040224877 drug delivery method of deglycosylated Vitamin D binding protein (DBP-maf) for angiogenesis inhibition; anticarcinogenic, antitumor agents
11/11/2004	US20040224875 Inhibitors of glutaminyl cyclase
11/11/2004	US20040224424 Nucleotide sequences comprising allelic variant of cytochrome p450 for use in diagnosis and treatment of cell proliferative, nervous system and cardiovascular disorders; pharmacodynamic profiles and drug screening
11/11/2004	US20040224356 Novel human enzymes of the metalloprotease family
11/11/2004	US20040224323 PAK5 screening methods
11/11/2004	US20040224316 Using phosphodiesterase 4 inhibitor to treat cognitive training disorders; learning enhancement and enzyme inhibitors
11/11/2004	US20040224314 G-protein coupled receptors
11/11/2004	DE10317369A1 proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen proNGF as pharmaceutically active agents for treating demyelinating diseases
11/11/2004	CA2533074A1 Regulation of guanine nucleotide exchange factor
11/11/2004	CA2524245A1 The use of azetidinecarboxamide derivatives in therapy
11/11/2004	CA2523852A1 Use of tyrosine kinase inhibitors for treating cerebral ischemia
11/11/2004	CA2523763A1 Fused pyrimidine derivative
11/11/2004	CA2523585A1 Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives
11/11/2004	CA2523331A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
11/11/2004	CA2523102A1 Substituted indoline and indole derivatives
11/11/2004	CA2523020A1 Use of derivatives of 2, 4-dihydro-[1,2,4]triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo)
11/11/2004	CA2522460A1 Beta-amyloid inhibitors and use thereof
11/11/2004	CA2521152A1 Use of a topical medicament comprising riluzole
11/11/2004	CA2520839A1 Quinoxalinone-3- one derivatives as orexin receptor antagonists
11/11/2004	CA2518753A1 Quinolone derivatives
11/10/2004	EP1475386A2 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction
11/10/2004	EP1475385A1 Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid
11/10/2004	EP1475382A1 Compounds as semaphorin inhibitors
11/10/2004	EP1475090A1 Drugs for mitochondrial diseases
11/10/2004	EP1475088A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
11/10/2004	EP1475086A2 Sibutramine metabolites
11/10/2004	EP1475085A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose
11/10/2004	EP1474445A1 Glycoisoforms of adiponectin and uses thereof
11/10/2004	EP1474443A1 Tolerogenic peptides from myelin basic protein
11/10/2004	EP1474442A2 Cytotoxic t-cell epitopes from chlamydia
11/10/2004	EP1474440A2 Coniosulphides and their derivatives, method for their production and use as medicaments
11/10/2004	EP1474434A2 The eaat2 promoter and uses thereof
11/10/2004	EP1474425A1 Deazapurines and uses thereof
11/10/2004	EP1474421A1 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity
11/10/2004	EP1474419A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
11/10/2004	EP1474416A1 Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
11/10/2004	EP1474414A1 Dihydro-thia-phenanthrene-carbonyl-guanidines, method for the production thereof, use thereof as a medicament or diagnostic reagent
11/10/2004	EP1474403A2 Urea derivatives and their use as vanilloid receptor antagonists
11/10/2004	EP1474401A2 Novel aryl- and heteroarylpiperazines
11/10/2004	EP1474399A1 Benzenesulfonamide derivatives as antipsychotic agents
11/10/2004	EP1474398A1 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use of the same as pharmaceuticals
11/10/2004	EP1474395A1 Nicotinamide derivates useful as p38 inhibitors
11/10/2004	EP1474394A1 Pyridineamido derivatives as inhibitors of monoamine oxidase (mao-b)
11/10/2004	EP1474393A1 Aryl ureas as kinase inhibitors
11/10/2004	EP1474384A1 Beta-amino ketones for the treatment of pain
11/10/2004	EP1474380A2 4-dedimethylamino tetracycline compounds
11/10/2004	EP1474158A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
11/10/2004	EP1474151A2 Methods of treatment of chronic immune disease
11/10/2004	EP1474150A2 Use of 2-alkoxyphenyl-substituted imidazotriazinones
11/10/2004	EP1474148A1 Treatment of neuroblastoma
11/10/2004	EP1474147A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
11/10/2004	EP1474140A1 2-oxazolamines and their use as 5-ht2b receptor antagonists
11/10/2004	EP1474139A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/10/2004	EP1474137A1 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
11/10/2004	EP1474129A1 Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k
11/10/2004	EP1474119A1 Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta
11/10/2004	EP1474093A2 Granzyme b inhibitors
11/10/2004	EP1370560B1 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
11/10/2004	EP1280803B1 Crystalline form ii of cabergoline
11/10/2004	EP1265880B1 Method for the preparation of citalopram

1 ... 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 ... 1833